Welcome to TDR’s review of the Top 5 Psychedelic developments for the week of May 2. Aside from presenting a synopsis of events, we provide market commentary to summarize the week that was for publicly-listed companies. 5. COMP360 Psilocybin Therapy Shows Potential In Exploratory Open-Label Studies For Anorexia Nervosa And Severe Treatment-Resistant Depression COMPASS Pathways plc (NASDAQ: […]
Devoted To Excellent Health